IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases

NCT02556593 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Carcinoma

Interventions

RADIATION: IMRT
RADIATION: WBRT
DRUG: erlotinib

Sponsor

Sun Yat-sen University